Stephen C. Knight joined Fidelity Biosciences in 2003 where he serves as President and Managing Partner. Dr. Knight has worked in the pharmaceutical and biotechnology industries for over twenty years. Prior to joining Fidelity, Dr. Knight was president and chief operating officer for EPIX. Before joining EPIX, Dr. Knight worked at Arthur D. Little Inc., specializing in mergers and acquisitions in the pharmaceutical industry and performed research at AT&T Bell Laboratories (now Lucent Technologies), the National Institutes of Health, and Yale University.

Dr. Knight currently serves as Chairman of the Board of Directors for EnVivo Pharmaceuticals and serves on the board of directors of CardioKine Inc., Proteostasis Therapeutics, FoldRX, Optegra Global Ltd., Respivert, Ltd, and U.S. Genomics. Dr. Knight previously served on the boards of several private and public health care companies including Ironwood Pharmaceuticals. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.